How Does a "Viscoelastic" Hemostasis Assay Differ from Traditional PT/PTT Testing? London

In the fast-paced environment of a modern clinical laboratory, the ability to provide rapid and accurate assessments of a patient’s clotting ability can be the difference between a successful surgical outcome and a life-threatening hemorrhage. For decades, the Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) have been the "gold standard" for screening coagulation disorders. However, as medical technology has advanced, a more dynamic method known as Viscoelastic Hemostasis Assay (VHA) has emerged to challenge these traditional tests. While PT and PTT provide a static snapshot of specific pathways, VHA offers a real-time, global view of the entire clotting process.

The Mechanistic Shift: Plasma vs. Whole Blood

The primary technical difference between traditional testing and viscoelastic assays lies in the sample type and what is actually being measured. PT and PTT tests are "plasma-based" assays. This means the blood sample must be centrifuged to remove cellular components like platelets and red blood cells before testing begins. These tests measure the time it takes for a fibrin clot to start forming in an acellular environment. While this is excellent for identifying deficiencies in specific clotting factors (the "liquid" part of the cascade), it completely ignores the "cellular" part of the equation. In vivo, clotting is a cell-based process where platelets and fibrinogen interact to create a stable structure.

Kinetic Measurement: Initiation vs. Clot Life Span

Traditional coagulation tests are essentially "stopwatch" tests; they measure the number of seconds until the first strands of fibrin appear. This only accounts for the first 5% of the clotting process. PT and PTT tell the clinician that clotting has started, but they offer zero information about whether the clot is strong enough to stop a bleed or how long it will last. Once that initial fibrin strand is detected, the test is over. This "blind spot" means that a patient could have a normal PT/PTT result but still be at risk of severe bleeding because their clot is fragile or breaking down too quickly.

Viscoelastic assays, however, track the entire life span of the clot. By using a rotating pin or cup to measure the physical tension of the blood as it solidifies, VHA records the kinetics of clot initiation, the speed of growth, the ultimate strength (Maximum Amplitude), and the eventual breakdown (fibrinolysis). For alab technician, this means they can provide data on whether a patient needs fresh frozen plasma (to fix initiation), cryoprecipitate (to fix strength), or antifibrinolytics (to stop the clot from dissolving). This "global" perspective allows for goal-directed therapy rather than empirical, blind transfusions.

Operational Speed and Point-of-Care Utility

In a critical bleeding scenario, "turnaround time" is the most vital metric. Traditional PT/PTT tests are typically performed in a centralized laboratory. The process involves transporting the sample, centrifuging it for 10 to 15 minutes, and then running the assay. This often leads to a delay of 45 to 60 minutes before a result reaches the surgeon. By the time the result arrives, the patient’s clinical status may have changed significantly, rendering the data obsolete. This "lag" often results in the over-transfusion of blood products as clinicians try to guess the underlying issue.

VHA is designed as a "Point-of-Care" (POC) test, meaning it can be situated directly in the operating room or the emergency department. Because it uses whole blood, the centrifugation step is eliminated. A lab technician can begin the test immediately, and actionable results—such as the "A5" or "A10" values (clot strength at 5 or 10 minutes)—are available much faster than a standard lab report. This speed allows for rapid, targeted resuscitation. Studies consistently show that VHA-guided protocols lead to better patient outcomes and less blood product wastage, making the role of the technician who operates these machines central to modern "Patient Blood Management."

Identifying Hyperfibrinolysis and Clot Stability

One of the most dangerous conditions in trauma and surgery is "hyperfibrinolysis"—a state where the body's natural clot-busting enzymes become overactive and dissolve clots as fast as they can form. Traditional PT, PTT, and even D-dimer tests are virtually useless for diagnosing this in an acute setting. They cannot show you the "disappearance" of a clot in real-time. Consequently, patients suffering from this condition may receive liters of blood products that simply "wash out" because the underlying breakdown mechanism isn't being addressed.

Contact seller Share